World Epilepsy Drug Market - Opportunities and Forecasts, 2017-2023 Epilepsy is a chronic brain disorder characterized by sudden and recurrent episodes of seizure. It is one of the most common neurological disorders worldwide, affecting people of all ages. Presently, around 50 million patients are living with epilepsy worldwide and about 2.4 million new cases are diagnosed annually. Moreover, majority of the epileptic cases are idiopathic, with no identifiable cause. At present, only symptomatic treatment through medication, surgery and implantable devices, is available, but there is no cure for epilepsy. This highlights the untapped market need for better therapeutics which would provide lucrative growth opportunities to industry players. Rising incidence of neurological disorders, higher incidence of birth related injuries, increasing road traffic injuries, growing disease awareness and rising patient base in developing countries, are the significant factors driving the global Epilepsy drug market.
Get sample copy of this report at : https://www.alliedmarketresearch.com/request-toc-and-sample/1497
Moreover, increasing R&D investment and launch of extended-release formulations are further expected to fuel the market growth. However, high cost of patented drugs and low accessibility to Epilepsy drugs in low and middle income countries, are likely to restrict the market growth. The global epilepsy drug market is segmented on the basis of drug type and geography. On the basis of drug type, the market is segmented into marketed drugs and pipeline drugs. The market, on the basis of marketed drugs is further segmented into first generation drugs (Phenytoin, Carbamazepine, Oxycarbazepine), second generation drugs (Levetiracetam, Lamotrigine, Topiramate) and third generation drugs (Lacosamide, Perampanel, Eslicarbazepine Acetate). Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA.
Key players in the market :
Pfizer Inc. Eisai Co. Ltd Novartis AG Sanofi S.A. UCB S.A. Abbott Laboratories GlaxoSmithKline plc
Get full summary of this at: https://www.alliedmarketresearch.com/epilepsy-drug-market